Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | SMAD family member 2 | Starlite/ChEMBL | No references |
Homo sapiens | TAR DNA binding protein | Starlite/ChEMBL | No references |
Homo sapiens | breast cancer 1, early onset | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | MH2 domain containing protein | SMAD family member 2 | 467 aa | 405 aa | 31.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | ATP dependent DNA ligase C terminal region family protein | 0.0012 | 0.0154 | 0.0154 |
Loa Loa (eye worm) | hypothetical protein | 0.0012 | 0.0154 | 0.0154 |
Brugia malayi | Pax transcription activation domain interacting protein | 0.0012 | 0.0154 | 0.0154 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0012 | 0.0154 | 0.5 |
Echinococcus granulosus | replication factor c subunit 1 | 0.0012 | 0.0154 | 0.031 |
Trichomonas vaginalis | replication factor C large subunit, putative | 0.0012 | 0.0154 | 0.5 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0076 | 0.4963 | 0.4963 |
Loa Loa (eye worm) | hypothetical protein | 0.0012 | 0.0154 | 0.0154 |
Wolbachia endosymbiont of Brugia malayi | NAD-dependent DNA ligase, Lig | 0.0012 | 0.0154 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0012 | 0.0154 | 0.5 |
Echinococcus granulosus | tar DNA binding protein | 0.0076 | 0.4963 | 1 |
Echinococcus multilocularis | nibrin | 0.0012 | 0.0154 | 0.031 |
Echinococcus multilocularis | replication factor c subunit 1 | 0.0012 | 0.0154 | 0.031 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.4963 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0012 | 0.0154 | 0.0154 |
Trichomonas vaginalis | RNA polymerase II ctd phosphatase, putative | 0.0012 | 0.0154 | 0.5 |
Toxoplasma gondii | ATPase, AAA family protein | 0.0012 | 0.0154 | 0.5 |
Treponema pallidum | DNA ligase (lig) | 0.0012 | 0.0154 | 0.5 |
Onchocerca volvulus | 0.0012 | 0.0154 | 0.5 | |
Trypanosoma brucei | BRCA1 C Terminus (BRCT) domain containing protein, putative | 0.0012 | 0.0154 | 0.5 |
Schistosoma mansoni | topbp1 | 0.0012 | 0.0154 | 0.031 |
Echinococcus multilocularis | tar DNA binding protein | 0.0076 | 0.4963 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0012 | 0.0154 | 0.0154 |
Toxoplasma gondii | poly(ADP-ribose) polymerase catalytic domain-containing protein | 0.0012 | 0.0154 | 0.5 |
Brugia malayi | TAR-binding protein | 0.0076 | 0.4963 | 0.4963 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0076 | 0.4963 | 0.4963 |
Echinococcus granulosus | nibrin | 0.0012 | 0.0154 | 0.031 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.4963 | 1 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0144 | 1 | 1 |
Schistosoma mansoni | chromosome transmission fidelity factor | 0.0012 | 0.0154 | 0.031 |
Loa Loa (eye worm) | hypothetical protein | 0.0012 | 0.0154 | 0.0154 |
Brugia malayi | topoisomerase | 0.0012 | 0.0154 | 0.0154 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0012 | 0.0154 | 0.5 |
Plasmodium vivax | replication factor C subunit 1, putative | 0.0012 | 0.0154 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.4963 | 1 |
Mycobacterium leprae | PROBABLE DNA LIGASE [NAD DEPENDENT] LIGA (POLYDEOXYRIBONUCLEOTIDE SYNTHASE [NAD+]) | 0.0012 | 0.0154 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.4963 | 1 |
Brugia malayi | RNA binding protein | 0.0076 | 0.4963 | 0.4963 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0012 | 0.0154 | 0.5 |
Giardia lamblia | Replication factor C, subunit 1 | 0.0012 | 0.0154 | 0.5 |
Plasmodium falciparum | replication factor C subunit 1, putative | 0.0012 | 0.0154 | 0.5 |
Trichomonas vaginalis | chromosome transmission fidelity factor, putative | 0.0012 | 0.0154 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.4963 | 1 |
Trypanosoma cruzi | FHA domain containing protein, putative | 0.0012 | 0.0154 | 0.5 |
Trichomonas vaginalis | RNA polymerase II ctd phosphatase, putative | 0.0012 | 0.0154 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0012 | 0.0154 | 0.5 |
Loa Loa (eye worm) | RNA binding protein | 0.0076 | 0.4963 | 0.4963 |
Trypanosoma cruzi | BRCA1 C Terminus (BRCT) domain containing protein, putative | 0.0012 | 0.0154 | 0.5 |
Trichomonas vaginalis | chromosome transmission fidelity factor, putative | 0.0012 | 0.0154 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0012 | 0.0154 | 0.5 |
Brugia malayi | hypothetical protein | 0.0012 | 0.0154 | 0.0154 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0012 | 0.0154 | 0.5 |
Mycobacterium ulcerans | NAD-dependent DNA ligase LigA | 0.0012 | 0.0154 | 0.5 |
Loa Loa (eye worm) | TAR-binding protein | 0.0076 | 0.4963 | 0.4963 |
Brugia malayi | DKFZp564C0469 protein | 0.0012 | 0.0154 | 0.0154 |
Entamoeba histolytica | Activator 1 140 kDa subunit, putative | 0.0012 | 0.0154 | 0.5 |
Chlamydia trachomatis | DNA ligase | 0.0012 | 0.0154 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0012 | 0.0154 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0012 | 0.0154 | 0.0154 |
Brugia malayi | hypothetical protein | 0.0012 | 0.0154 | 0.0154 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0144 | 1 | 1 |
Schistosoma mansoni | DNA ligase IV | 0.0012 | 0.0154 | 0.031 |
Schistosoma mansoni | topbp1 | 0.0012 | 0.0154 | 0.031 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 1 uM | PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 7.0795 uM | PubChem BioAssay. qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 11.2202 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of binding or entry into cells for Lassa Virus. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID463114, AID540249] | ChEMBL. | No reference |
Potency (functional) | 17.7828 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Potency (functional) | 20.5962 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 25.1189 uM | PubChem BioAssay. qHTS Assay for Inhibitors of the HIV-1 protein Vpr. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 25.929 uM | PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648] | ChEMBL. | No reference |
Potency (functional) | 28.1838 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID540262] | ChEMBL. | No reference |
Potency (functional) | 31.6228 uM | PubChem BioAssay. qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 50.1187 uM | PubChem BioAssay. qHTS of PTHR Inhibitors: Primary Screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 100 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID540273] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.